Clinical Trial Update: Apixaban for the Prevention of Venous Thromboembolism in Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating apixaban for prevention of venous thromboembolism in cancer patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Venous Thromboembolism

Drugs mentioned

• Apixaban (apixaban)

Snippet

Sponsor: Ottawa Hospital Research Institute | Conditions: Venous Thromboembolism, Cancer | Phase 2 | Status: COMPLETED